Atogepant, a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, has shown potential in prevention of migraine at a range of doses, according to a presentation at the recent American Headache Society conference (AHS 2019).
Treatment with onabotulinumtoxinA significantly improves headache-related outcomes in patients with chronic migraine (CM) regardless of their response status, according to a study presented at AHS 2019.
Patients receiving topiramate to prevent chronic migraines could potentially switch to onabotulinumtoxinA injections to reduce the frequency of their headaches, according to results of the FORWARD* study presented at the recent American Headache Society conference (AHS 2019).
Fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, significantly reduces the number of migraine days in patients with chronic migraine (CM) or episodic migraine (EM), according to the FOCUS* study presented at AHS 2019.
An active lifestyle, regardless of vascular risk, may delay the progression of Alzheimer’s disease (AD) by slowing down cognitive decline and neurodegeneration, according to a study presented at the Alzheimer’s Association International Conference (AAIC 2019).
Early detection, intervention and adoption of a healthy lifestyle are the key to ending dementia, according to Professor Vincent Mok of the Division of Neurology, Faculty of Medicine, Chinese University of Hong Kong.
A recent analysis of 1,289 individuals across normal, overweight and obese Body Mass Index (BMI) ranges demonstrated that higher BMI and waist circumference values were significantly associated with thinner brain cortices.